TNF and juvenile idiopathic arthritis: Unfortunately, a considerable group of JIA/JDM patients do not respond to anti-TNF therapy (27, 49, 53) and anti-TNF agents are immunogenic (69), with 50% of patients developing anti-drug antibodies leading to resistance to therapy and disease progression.